• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gamida Cell Ltd (NQ: GMDA )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Apr 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Gamida Cell Ltd

    < Previous 1 2 3 4 5 6 7 Next >
    Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference
    From Gamida Cell Ltd.
    Via Business Wire
    The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Gamida Cell Posts Updated Omidubicel Data In Blood Cancer Patients
    Via Benzinga
    Gamida Cell Shares Jump On FDA Nod To Cell Therapy Trial In Blood Cancer Settings
    Via Benzinga
    Gamida Cell: Q4 Earnings Insights
    Gamida Cell (NASDAQ:GMDA) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
    Via Benzinga
    Gamida Cell: Q1 Earnings Insights
    Gamida Cell (NASDAQ:GMDA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Gamida Cell reported in-line EPS of... 
    Via Benzinga
    Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update
    From Gamida Cell Ltd.
    Via Business Wire
    Earnings Preview: Gamida Cell
    Gamida Cell (NASDAQ:GMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Gamida Cell will... 
    Via Benzinga
    Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022
    From Gamida Cell Ltd.
    Via Business Wire
    Cell Therapy-Focused Gamida Plans To Cut 10% Of Staff
    Gamida Cell Ltd (NASDAQ: GMDA) will terminat 
    Via Benzinga
    Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
    From Gamida Cell Ltd.
    Via Business Wire
    The Daily Biotech Pulse - Tuesday, April,26
    Here's a roundup of top developments in the biotech space over the last 24 hours. 
    Via Talk Markets
    The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201
    From Gamida Cell
    Via Business Wire
    Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference
    From Gamida Cell Ltd.
    Via Business Wire
    The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
    From Gamida Cell Ltd.
    Via Business Wire
    Earnings Scheduled For March 15, 2022
    Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi... 
    Via Benzinga
    Preview: Gamida Cell's Earnings
    Gamida Cell (NASDAQ:GMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts estimate... 
    Via Benzinga
    Merck (MRK) Outperforms Industry, What's In Store For 2022?
    Merck boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales. 
    Via Talk Markets
    The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
    Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
    Via Benzinga
    Gamida Cell Shares Surge On Rolling Omidubicel Marketing Application In US
    Gamida Cell Ltd (NASDAQ: GMDA) has initiated the Biologics License Application (BLA)  
    Via Benzinga
    Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Provides Key Program Updates and 2022 Financial Guidance
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Ltd. (NASDAQ:GMDA) Investor Alert: Investigation over Potential Wrongdoing
    San Diego, CA -- (SBWIRE) -- 01/27/2022 -- Certain directors of Gamida Cell Ltd are under investigation over potential breaches of fiduciary duties. 
    Via SBWire
    48 Biggest Movers From Yesterday
    Gainers Aptorum Group Limited (NYSE: APM) shares jumped 38.5% to close at $1.69 on Thursday after the company announced it received FDA Orphan Drug designation for... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.